Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$839M |
| 2 |
Amazon
AMZN
|
+$810M |
| 3 |
Tesla
TSLA
|
+$644M |
| 4 |
TSMC
TSM
|
+$546M |
| 5 |
Johnson & Johnson
JNJ
|
+$389M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$891M |
| 2 |
Home Depot
HD
|
+$441M |
| 3 |
JPMorgan Chase
JPM
|
+$335M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$317M |
| 5 |
ASML
ASML
|
+$315M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.84% |
| 2 | Technology | 15.57% |
| 3 | Consumer Discretionary | 11.88% |
| 4 | Consumer Staples | 10.09% |
| 5 | Financials | 9.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3076
Vanguard Morningstar Mega Cap Value ETF
MGV
$13.8B
| $401K | ﹤0.01% |
+3,900
| New | +$392K |
|
3077
Universal Logistics Holdings
ULH
$507M
| $401K | ﹤0.01% |
12,000
-33,400
| -74% | -$1.17M |
|
|
RAIN
3078
DELISTED
Rain Oncology Inc. Common Stock
RAIN
| $401K | ﹤0.01% |
50,100
+28,100
| +128% | +$176K |
|
3079
NextDecade
NEXT
$1.91B
| $400K | ﹤0.01% |
80,900
+46,827
| +137% | +$269K |
|
3080
Virgin Galactic
SPCE
$512M
| $400K | ﹤0.01% |
5,745
+4,025
| +234% | +$376K |
|
3081
Vanguard Energy ETF
VDE
$10.6B
| $400K | ﹤0.01% |
3,300
-7,000
| -68% | -$852K |
|
3082
Xtant Medical Holdings
XTNT
$42.8M
| $400K | ﹤0.01% |
606,310
-20,900
| -3% | -$13.7K |
|
|
CEI
3083
DELISTED
Camber Energy, Inc
CEI
| $400K | ﹤0.01% |
+198,213
| New | +$1.25M |
|
3084
iShares Emerging Markets Dividend ETF
DVYE
$1.2B
| $398K | ﹤0.01% |
+16,516
| New | +$395K |
|
3085
Everest Group
EG
$14.2B
| $398K | ﹤0.01% |
1,200
-19,400
| -94% | -$6.04M |
|
3086
Black Diamond Therapeutics
BDTX
$117M
| $397K | ﹤0.01% |
220,613
+2,913
| +1% | +$5.25K |
|
|
BNSO
3087
DELISTED
Bonso Electronic International
BNSO
| $397K | ﹤0.01% |
131,600
-6,800
| -5% | -$22.4K |
|
3088
Broadwind
BWEN
$124M
| $396K | ﹤0.01% |
221,252
+106,952
| +94% | +$201K |
|
3089
D.R. Horton
DHI
$41.7B
| $396K | ﹤0.01% |
+4,438
| New | +$356K |
|
|
YRD
3090
Yiren Digital
YRD
$106M
| $396K | ﹤0.01% |
289,343
+2,378
| +0.8% | +$2.73K |
|
3091
Schwab Fundamental US Large Company Index ETF
FNDX
$27.6B
| $395K | ﹤0.01% |
22,200
-71,400
| -76% | -$1.26M |
|
3092
ORIX
IX
$43.6B
| $395K | ﹤0.01% |
24,500
-74,500
| -75% | -$1.13M |
|
|
SSBK
3093
DELISTED
Southern States Bancshares
SSBK
| $394K | ﹤0.01% |
13,600
+2,107
| +18% | +$59.7K |
|
|
STRM
3094
DELISTED
Streamline Health Solutions
STRM
| $394K | ﹤0.01% |
16,605
+587
| +4% | +$14.3K |
|
3095
Cognyte Software
CGNT
$673M
| $393K | ﹤0.01% |
126,300
-39,400
| -24% | -$116K |
|
|
SPPI
3096
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $393K | ﹤0.01% |
1,066,400
+69,000
| +7% | +$29.1K |
|
3097
iShares Core 80/20 Aggressive Allocation ETF
AOA
$3.29B
| $390K | ﹤0.01% |
6,530
+330
| +5% | +$19.5K |
|
|
MAGN
3098
Magnera Corp
MAGN
$438M
| $390K | ﹤0.01% |
+10,800
| New | +$441K |
|
|
COE
3099
51Talk Online Education Group
COE
$119M
| $388K | ﹤0.01% |
61,575
-4,775
| -7% | -$32.3K |
|
3100
Jerash Holdings
JRSH
$67.3M
| $387K | ﹤0.01% |
99,440
+12,700
| +15% | +$53.3K |
|
Similar funds
Jim Simons's Q4 2022 Portfolio in Review
As of Q4 2022, Jim Simons held 4,601 positions worth $73.1B, up 3.4% from $70.7B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jim Simons's Q4 2022 filing shows 626 new, 1,390 increased, 2,018 reduced and 524 closed positions. Its largest new stake was Johnson & Johnson: 2,254,125 shares worth $398M. The largest sale was Microsoft, an estimated $891M.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2022 buy was Johnson & Johnson: 2,254,125 shares worth $398M.
- Jim Simons added most to Apple in Q4 2022, an estimated $839M increase.
- Jim Simons's biggest Q4 2022 reduction was Novo Nordisk, cutting an estimated $317M.
- Jim Simons fully exited Microsoft in Q4 2022, selling an estimated $891M.
- Jim Simons's ten largest holdings make up 11% of its $73.1B portfolio in Q4 2022.
- Jim Simons opened 626 new positions and closed 524 in Q4 2022.
- Jim Simons's portfolio value rose 3.4% quarter-over-quarter to $73.1B.
Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.